Midacina

Quick links to important sections

Midacina

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Midacina

Property Description
Active Ingredients Fluocinonide, Gramicidin, Neomycin
Form Topical Solution, Cream, Ointment, or Gel
Pharmacological Class Topical Corticosteroid and Anti-infective
General Purpose Managing inflammation and bacterial infection concurrently
Origin Synthetic and Peptide-derived components

What Type of Medicine is Midacina?

Midacina is classified as a fixed-dose combination pharmaceutical preparation, falling under the pharmacological category of a Topical Corticosteroid and Anti-infective. This identity indicates that the product integrates multiple distinct therapeutic agents into a single formulation, engineered for localized application via the Topical route of administration. Its components include the potent corticosteroid Fluocinonide, and the antibiotics Neomycin and Gramicidin. The inclusion of this specific corticosteroid provides a potent anti-inflammatory action. The formulation is recognized for its ability to quickly suppress significant tissue reactions, differentiating it from low-potency, single-component topical steroids.

Composition: Steroid and Dual Antibiotic Ingredients

The preparation contains three essential active ingredients: the potent synthetic corticosteroid Fluocinonide, the aminoglycoside antibiotic Neomycin, and the peptide antibiotic Gramicidin. The inclusion of Fluocinonide provides the drug's powerful anti-inflammatory and anti-pruritic properties, while the combined action of Neomycin and Gramicidin provides broad-spectrum defense against bacterial pathogens. Neomycin is an established compound used in treating infections. Midacina is typically provided in various common dosage form(s), such as an Ointment, Cream, or Topical Solution, with the base/vehicle designed to ensure effective delivery of these three components—sourced from synthetic and natural-derived processes—to the affected site.

What is the General Purpose of This Combination?

The general purpose of the Midacina formulation is to provide comprehensive, localized relief for irritated skin conditions where a bacterial infection is either present or highly anticipated. This composition is commonly used when treating a flare-up of chronic inflammation that has become contaminated or when preventing a secondary infection in compromised skin. By combining a potent anti-inflammatory agent with two complementary antibiotics, the drug efficiently addresses both the underlying tissue reaction and the microbial contamination. This integrated approach ensures that the intense redness, swelling, and itching are calmed rapidly, while the bacterial burden is simultaneously managed, promoting a swift, singular resolution to the complex dermatological concern.

What side effects are possible with Midacina?

Possible Side Effects and Safety Information

The safety profile for Midacina, a combination of a potent corticosteroid (Fluocinonide) and anti-infectives (Neomycin and Gramicidin), is defined by both local and potential systemic effects documented in regulatory labeling. The adverse reactions are broadly categorized by the affected organ system, known as System Organ Classes.

Local adverse reactions, classified as infrequent with topical corticosteroid use, involve Skin and Subcutaneous Tissue Disorders. These include burning, itching, irritation, dryness, and skin structure changes such as skin atrophy (thinning) and striae (stretch marks). These effects may be more pronounced with prolonged use or application under occlusive dressings.

Serious Systemic Adverse Reactions

The most clinically significant safety information concerns the potential for systemic toxicity due to drug absorption. Systemic absorption of the potent corticosteroid can lead to Endocrine Disorders, including Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing’s syndrome. Intracranial hypertension is also documented. The Neomycin component carries an official risk of Ototoxicity (hearing or balance impairment) and Nephrotoxicity (kidney damage), linked to significant systemic absorption.

Population-Specific Safety Considerations

Official regulatory documents specifically state that pediatric patients have greater susceptibility to systemic effects, including HPA axis suppression and resulting issues such as linear growth retardation and delayed weight gain.

Overdose and Emergency Response

The overdose profile for Midacina is defined by the potential for systemic absorption of its active components following excessive application, prolonged use over large surface areas, or accidental oral ingestion. Overdose of the corticosteroid component, Fluocinonide, may lead to reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression, clinical manifestations resembling Cushing's syndrome, hyperglycemia, and glucosuria.

The systemic absorption of the Neomycin antibiotic component carries the documented risk of nephrotoxicity and neuromuscular blockade. The most severe outcome is the potential for irreversible sensorineural ototoxicity, which represents permanent auditory damage, and the risk of renal failure. Documented severe outcomes also include glucocorticosteroid insufficiency upon withdrawal of the product.

Regulatory guidance requires patients to seek immediate medical attention or contact a Poison Control center following accidental oral ingestion or the observation of any clinical signs of systemic toxicity. Management is strictly symptomatic and supportive, as no specific antidote is known. Monitoring requirements include periodic testing, such as the ACTH stimulation test, to evaluate for HPA suppression. Pediatric patients are noted to have increased susceptibility to systemic effects, including the potential for intracranial hypertension.

Therapeutic Uses of Midacina

What Midacina Treats: Main Uses and Benefits

Midacina is commonly used across conditions presenting with acute episodes and symptoms that interfere with daily functioning, such as inflammatory skin diseases. The medication is used in situations involving certain distressing symptoms associated with recurrent or episodic manifestations of eczema, various forms of dermatitis, and certain psoriatic lesions. This medication assists with the management of symptoms that become more disruptive during flare-ups, relevant for easing symptoms related to inflammatory or irritative states, such as redness (erythema), swelling, and the associated discomfort of intense itching (pruritus). The symptomatic relief offered contributes to improved comfort during periods of heightened symptoms, which helps patients cope more steadily with difficult episodes.

Addressing Bacterial Contamination in Compromised Skin

The medication is applied in clinical settings that involve acute or unstable symptom patterns where a primary inflammatory condition has become complicated by superficial bacterial colonization. These combination agents are designed for use in scenarios where infection of the skin is present and additional management of discomfort is required due to microbial involvement. This combination is considered relevant when symptoms cluster into patterns requiring supportive management, such as crusting, weeping, or oozing lesions resulting from infection. This assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.


Quick Fact: Support for Inflammatory Symptoms and Microbial Signs Midacina is applied when symptoms create noticeable physiological strain and additional symptomatic support is needed for the intense itching and secondary bacterial signs often present in chronic skin conditions.

Eligibility and Restrictions for Use

Who can and cannot use Midacina?

The population eligibility for Midacina, a combination topical drug, is strictly defined by government regulatory labeling concerning contraindications and restrictions.

Contraindications (Who Must Not Use):

The medicine is absolutely contraindicated for patients with a known history of hypersensitivity to any of its three active ingredients: Fluocinonide, Neomycin, or Gramicidin. Additionally, the label prohibits use in individuals with rosacea or perioral dermatitis. Use is also contraindicated if the eardrum is perforated and application to the ear is intended.

Age and Condition Restrictions:

  • Pediatric Use: Use in children younger than 12 years of age is generally not recommended for certain indications. For all children, administration must be limited to the least amount and shortest duration compatible with efficacy due to the increased risk of systemic absorption.
  • Pregnancy and Lactation: Use during pregnancy is restricted and requires caution; it must not be used extensively or for prolonged periods. Caution is also advised for nursing mothers.
  • Conditional Use: The use of Midacina is restricted over large surface areas, under occlusive dressings, on the face, groin, or axillae, and for durations exceeding two consecutive weeks.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile for Midacina, containing Neomycin and Fluocinonide, is structured around the potential for systemic absorption of its active components, which dictates interaction risk. Due to the Neomycin component, co-administration with other medicinal products known to be nephrotoxic or neurotoxic is subject to regulatory restriction because of the documented risk of additive pharmacodynamic toxicity.

Pharmacodynamic Interaction Restrictions

Official labeling identifies the following categories of medicinal products that may increase interaction risk if systemic absorption occurs:

  • Nephrotoxic and Neurotoxic Drugs: Concomitant use with other aminoglycosides or agents such as Cisplatin or Vancomycin should be restricted due to the potential for additive effects on the kidneys and the nervous system.
  • Neuromuscular Agents: Concomitant use with neuromuscular blocking agents (e.g., tubocurarine, succinylcholine) may result in an enhanced risk of neuromuscular blockade and respiratory depression.
  • Potent Diuretics: Co-administration with potent diuretics, such as Furosemide or Ethacrynic Acid, is noted in regulatory warnings to enhance the neurotoxic effects of Neomycin.

Exposure-Dependent Interaction Constraints

The risk of systemic exposure is officially recognized as being significantly increased by several conditions, thereby raising the potential for clinically significant interactions. These conditions include application over large surface areas, prolonged use, and the use of occlusive dressings or tight-fitting garments. Furthermore, patients with pre-existing renal impairment have a heightened susceptibility to these toxic interactions due to the reduced clearance of absorbed Neomycin.

Mechanism of Action

The mechanism of Midacina is characterized by two distinct categories of mechanistic action: modulation of the host's inflammatory response and direct antimicrobial activity.

Steroid Agonism and Anti-Inflammatory Cascade Suppression

Fluocinonide functions as an agonist at the cytosolic Glucocorticoid Receptor (GR), initiating a genomic cascade. This binding enhances the expression of proteins, including Lipocortin-1, which inhibits the enzyme Phospholipase A2. By blocking this early step, the mechanism restricts the release of Arachidonic Acid—the precursor to major inflammatory mediators like prostaglandins and leukotrienes—resulting in decreased local cellular permeability and vasoconstriction.

Complementary Bactericidal Attack on Microbial Integrity

The formulation integrates the two antibiotics, Neomycin and Gramicidin, which use distinct mechanistic pathways to ensure broad-spectrum antimicrobial activity. Neomycin binds to the bacterial 30S ribosomal subunit, causing errors in protein synthesis that lead to cellular dysfunction. Gramicidin achieves its bactericidal effect by physically inserting into the bacterial cell membrane, forming ion channels that rapidly dissipate the essential transmembrane potential. This dual-target mechanism leads to the cessation of bacterial functionality and cellular integrity failure.

Dosage and Administration Information

How to Use Midacina: Official Administration Guidelines

Midacina is a combination product used according to established administration protocols for high-potency topical corticosteroid and anti-infective agents. The general principle for use is to provide short-term, localized application for the management of acute episodes.


Administration Protocol

The product is approved for the Topical route of administration and must only be used externally on the skin. It is available in various forms, including Cream, Ointment, Solution, or Gel.

Feature Official Use Instructions
Application Method Apply a thin layer to the affected area of the skin and rub in gently.
Dosing Frequency The schedule ranges from once or twice daily (for 0.1% strength) to two to four times daily (for 0.05% strength).
Duration of Use Treatment is generally limited to 2 consecutive weeks. Use is to be discontinued once the condition is controlled.
Quantity Restriction The total dosage should not exceed 60 grams per week for high-potency formulations.

Specific Administration Conditions

Certain restrictions apply for proper use. The treated skin area should not be covered with an occlusive dressing or tight bandages unless a healthcare professional explicitly directs it. Contact with the eyes, face, groin, and underarm areas should generally be avoided during application, as these areas are more susceptible to systemic absorption or adverse local effects. In terms of age-specific use, certain high-potency formulations are not recommended for use in children younger than 12 years of age. When used in children, the application must be limited to the least effective amount and duration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Midacina

Research for Conditions Associated with Acute or Disruptive Episodes

Midacina was studied for use in managing skin conditions, such as eczema, dermatitis, and psoriasis, that are characterized by fluctuating or episodic manifestations where superficial bacterial colonization appears to be present. Research explored how the components were studied in combination in settings involving periods of heightened symptoms that are often disruptive to daily functioning. The primary research exploring this combination involves short-term Randomized Controlled Trials (RCTs) and comparative Phase 3 studies that research examined the therapeutic components. These study designs explored how symptoms evolved in the observed populations.

Studies monitored objective measurements like the Investigator Global Assessment (IGA) to assess severity, alongside assessments of patient-reported outcomes describing perceived discomfort. These outcomes was studied for physical discomfort such as itching and redness. Findings describe patterns observed in the studies, where the combination was evaluated in research exploring short-term symptom changes over defined time intervals.


Study Designs and Outcomes Monitored

The research base primarily relies on controlled study designs. The outcomes monitored was studied for physical signs of inflammation and microbial involvement. For example, studies monitored outcomes such as the magnitude of physical discomfort and patterns related to inflammation, such as redness and swelling. Researchers also studies monitored systemic markers, such as hypothalamic-pituitary-adrenal (HPA) axis function, to understand potential absorption characteristics of the corticosteroid component. The overall evidence level is broadly labeled as Moderate, which data show patterns related to the anti-inflammatory component and the complementary anti-infective components.


What Research Remains Uncertain

The treatment periods studies monitored in the core efficacy trials were typically short-term, often spanning two weeks or less. Consequently, long-term effects are not fully established. The research provides limited information for long-term outcomes, such as the duration of observed symptom patterns over several months, or the effects related to repeated, extended use. Furthermore, while the components are well-studied individually, comparative evidence is lacking for the specific three-drug formulation in publicly cited clinical trials reviewed by regulators. Research does not determine whether an individual will respond similarly outside of the specific conditions under which the studies were conducted.

Frequently Asked Questions (FAQ)

Common questions about Midacina (FAQ)


Q: What should I do if I miss a dose of Midacina?

Official patient labeling suggests that if a dose is missed, application may be made as soon as it is remembered. However, if it is almost time for the next scheduled application, the missed dose is typically skipped, and the regular schedule is continued. Using a double dose to compensate for a missed application is generally not recommended in product information.


Q: Is it better to take Midacina in the morning or evening?

Regulatory documents provide instructions for the frequency of application (e.g., once or twice daily) but do not specify a preferred time of day (morning or evening). Application frequency is determined by the healthcare provider.


Q: Can Midacina cause fatigue or drowsiness?

Drowsiness is not explicitly listed as a common side effect of topical use. However, systemic absorption of the potent corticosteroid component may lead to HPA axis suppression—a condition that can cause symptoms like unusual tiredness or weakness. If signs such as unusual tiredness or weakness occur, consultation with a healthcare professional is generally advised.


Q: How long does a course of Midacina treatment usually last?

According to official prescribing information, treatment with high-potency formulations of Midacina is generally limited to two consecutive weeks. Use of the product is typically discontinued once the skin condition is controlled, and the total dosage should not exceed 60 grams per week.


Q: Is it normal to feel nauseous when starting Midacina?

Nausea or upset stomach is not typically listed as a common local side effect for this topical drug. However, nausea can be a symptom related to adrenal insufficiency, which is a serious systemic effect linked to excessive corticosteroid absorption. If signs such as nausea occur, consultation with a healthcare professional is generally advised.


Q: Why is Midacina sometimes used for chronic conditions?

Midacina is indicated for managing inflammatory skin disorders like eczema and psoriasis, which are chronic conditions. The drug is typically prescribed for the short-term management of acute flare-ups or episodic manifestations of these conditions when a bacterial infection is also present or anticipated.


Q: Can Midacina be taken during pregnancy?

The use of Midacina during pregnancy is restricted and requires caution. Official documents state it must not be used extensively or for prolonged periods due to potential risk. Consultation with a healthcare professional is necessary if pregnancy occurs during the use of this medication.


Q: Does Midacina cause weight gain or loss?

Significant weight gain, particularly around the midsection, or unexplained weight loss are not common local side effects, but they can be symptoms of serious systemic reactions. These include Cushing’s syndrome or adrenal insufficiency, which are linked to the absorption of the corticosteroid component.


Q: Is Midacina used to treat infections?

Yes, Midacina is designed for dual action. Its formulation includes two antibiotics, Neomycin and Gramicidin, which provide broad-spectrum antimicrobial activity. This allows the product to manage microbial contamination concurrently with inflammation.


Q: Can Midacina cause skin sensitivity or a rash?

Yes, common local adverse reactions listed in the official safety profile include skin reactions such as burning, itching, and irritation. Additionally, the drug has been associated with allergic contact dermatitis, which is a type of skin rash.


Q: Why do some patients report headaches when taking Midacina?

Headache is listed as a less common adverse reaction. It may be a symptom of a more serious, rare systemic effect linked to corticosteroid absorption, such as intracranial hypertension (increased pressure around the brain) or Cushing’s syndrome.


Q: Is Midacina effective for acute versus chronic pain?

The product is indicated for conditions characterized by episodic manifestations and is studied primarily in short-term clinical trials. This suggests that its intended and evidenced use is for acute flare-ups and not for long-term management of chronic pain.


Q: What happens if you stop taking Midacina suddenly?

If the drug is stopped suddenly, especially after prolonged use or use over a large area, there is a risk of adrenal insufficiency. This condition occurs when the body's adrenal glands do not produce enough natural steroid hormones, which can result in symptoms like severe tiredness and muscle weakness.


Q: Can people with kidney problems take Midacina?

Official warnings state that people with pre-existing renal (kidney) impairment have a heightened susceptibility to systemic toxic interactions from the absorbed Neomycin component. This is due to the reduced ability of the kidneys to clear the drug. Use in this population may necessitate increased caution and restriction.


Q: How reliable is the clinical evidence supporting Midacina's use?

The overall evidence level supporting the use of Midacina is generally labeled as Moderate. The research base relies on short-term Randomized Controlled Trials that examined changes in symptoms, such as redness and discomfort, over defined periods.


Q: Does Midacina have any known drug-disease interactions I should be aware of?

Yes, regulatory documents highlight that pre-existing renal impairment increases the risk of toxic interactions due to the Neomycin component. The medication is also contraindicated (should not be used) for patients with rosacea, perioral dermatitis, or a perforated eardrum.


Q: Can Midacina be crushed or split?

Midacina is a topical product available in forms like a cream, ointment, or solution, and it is intended solely for external application to the skin. Since it is not an oral tablet or capsule, the concept of crushing or splitting does not apply.


Q: Why is Midacina sometimes mentioned in discussions about autoimmune conditions?

Midacina contains Fluocinonide, a potent corticosteroid known to suppress the inflammatory cascade. While it is indicated for conditions like eczema and psoriasis, which are often discussed in the context of immune or autoimmune dysfunction, the drug is specifically for localized, short-term management of flare-ups.


Q: Does Midacina interact with medications for diabetes?

Systemic absorption of the corticosteroid component can potentially cause hyperglycemia, which is high blood sugar. Regulatory warnings advise caution when using the drug in patients with diabetes, as the medication may make the pre-existing condition worse.

How should Midacina be stored and disposed of?

Storage Conditions

Midacina must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F), to maintain its chemical stability. The container must be kept tightly closed in the original packaging and stored away from excess heat and moisture. It is an official regulatory requirement that the product must not be frozen.

All medication must be stored out of the sight and reach of children.


Disposal Instructions

Disposal of unused or expired Midacina must follow local pharmaceutical waste regulations. The product must not be poured into drains or flushed down the toilet, as it is not on the list of medicines recommended for flushing. If a local drug take-back program is unavailable, the unused product should be mixed with an undesirable substance (e.g., used coffee grounds) in a sealed bag and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Midacina found in:

A-Z Index: